Approximately 1.5 million American adults have a chronic disease called lupus. More than 90% of people who have lupus are female. In the United States, lupus is more common in people of color African Americans, Hispanics/Latinos, Asian Americans, Native Americans, Native Hawaiians and Pacific Islanders than in the Caucasian population. It also appears that lupus develops at an earlier age and is more severe among members of these ethnic groups.
Lupus is a chronic inflammatory disease that can affect various parts of the body, including the skin, joints, blood and kidneys. Approximately two-thirds of lupus patients develop skin symptoms including sores or flaky red spots on the arms, hands, face, neck or back; mouth or lip sores; a scaly, red or purple raised rash on the face, neck, scalp, ears, arms and chest.
Currently there is no cure for lupus; the goal of treatment is to control symptoms, prevent flares and complications. The cornerstone of lupus skin disease therapy includes topical corticosteroids (glucocorticoids). However, ongoing glucocorticoid treatment contributes to adverse treatment effects. The untoward effect of topical corticosteroids includes atrophy, telangiectasia, striae distensae, folliculitis, acne, and purpura. Topical corticosteroids can also inhibit the skin’s ability to fight against bacterial or fungal infections. Additionally, the repair of skin damage due to lupus is often inadequate leaving the skin vulnerable to subsequent damage.
Maállo is a novel skin cream that expands therapeutic options for the management of lupus skin symptoms. As a post therapeutic (after the skin condition has stabilized) Maállo Cream supports the structure and function of the skin layers to facilitate healing of lupus induced rash and sores. Maállo also modifies the inflammatory stimulus within the skin layers to reduce the incident and severity of subsequent lupus skin symptoms.
As a post therapeutic, Maállo uniquely maintains the integrity of skin for those affected by lupus.
Even More Helpful For Women With Lupus . . .
World Lupus Day is 10 May 2013; as a contribution to Lupus Awareness Kathá Soma Therapeutics is providing a complimentary lip balm with each Maállo skin cream order placed during the month of May 2013.
For more information about Maállo Therapeutic Skin Cream click here.
Glucocorticoids have anti-inflammatory effects and are used to treat conditions that involve inflammation. Synthetic or semisynthetic glucocorticoids, derived chiefly from cortisol, include prednisone, prednisolone, dexamethasone, methylprednisolone, triamcinolone, and betamethasone.
Maállo Skin Cream and Lip Balm are manufactured and distributed by Kathá Soma Consumer Healthcare. Kathá Soma therapeutic formulas help people living with cancer, chronic disease or slow cell renewal due to aging, minimize their signs & symptoms, achieve daily comfort and maintain quality of life.
To learn more about Kathá Soma Consumer Healthcare visit http://www.Katha-Soma.com
Kátha Soma Consumer Healthcare manufactures and distributes skin care therapeutics and medical food. DISCLAIMER: Kátha Soma does not provide medical advice, diagnosis or treatment. The information provided is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.